TortsProf Blog

Editor: Christopher J. Robinette
Southwestern Law School

Monday, April 1, 2024

MDL for Weight Loss and Diabetes Drugs in Philly

Dozens of lawsuits accuse Novo Nordisk or Eli Lilly, manufacturers of GLP-1 agonists, of failure to warn about the side effects of their drugs.  GLP-1 agonists are used to treat obesity and diabetes.  The alleged side effects include digestive symptoms, such as gallbladder removal or gastroparesis (a disorder that slows or stops the movement of food from the stomach to the small intestine).  Many of the drugs are very popular; they include Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro.  Novo Nordisk and Eli Lilly deny any wrongdoing.  U.S. District Judge Gene E. K. Pratter of the Eastern District of Pennsylvania is overseeing the MDL.  The USA Today story is here.

Current Affairs, MDLs and Class Actions | Permalink


Post a comment